Back to top
more

Akorn, Inc. (AKRX)

(Real Time Quote from BATS)

$12.88 USD

12.88
13,663,138

-6.82 (-34.62%)

Updated Apr 23, 2018 03:48 PM ET

Add to portfolio

5-Strong Sell         5

D Value | F Growth | D Momentum | F VGM

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

View All Zacks #1 Ranked Stocks

Trades from $1

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1 Strong Buy 25.71%
2 Buy 18.12%
3 Hold 9.91%
4 Sell 5.49%
5 Strong Sell 2.29%
S&P 500 9.79%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Brokerage Reports

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

Research for AKRX

 

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

0 items in cart

Akorn, Inc. [AKRX]

Reports for Purchase

Showing records 1 - 20 ( 37 total )

Company: Akorn, Inc.

Industry: Medical - Generic Drugs

Record: 1

04/17/2018

Company Report

Pages: 10

ValuEngine Detailed Valuation Report for AKRX

Provider: ValuEngine, Inc

Price: 25.00

Research Provided by a Third Party

Company: Akorn, Inc.

Industry: Medical - Generic Drugs

Record: 2

06/26/2013

Company Report

Pages: 3

Research Coverage of AKRX Under Review

Provider: BRINSON PATRICK SECURITIES CORPORATION

Price: 10.00

Research Provided by a Third Party

Company: Akorn, Inc.

Industry: Medical - Generic Drugs

Record: 3

05/08/2013

Company Report

Pages: 7

Delays, lumps and newbies hit Q1 while pipeline value is intact.

Provider: BRINSON PATRICK SECURITIES CORPORATION

Analyst: HIGGINS M

Price: 25.00

Research Provided by a Third Party

Company: Akorn, Inc.

Industry: Medical - Generic Drugs

Record: 4

01/22/2013

Company Report

Pages: 8

Pipeline Value Leads to Our Higher Price Target, $15 to $18

Provider: BRINSON PATRICK SECURITIES CORPORATION

Analyst: HIGGINS M

Price: 25.00

Research Provided by a Third Party

Company: Akorn, Inc.

Industry: Medical - Generic Drugs

Record: 5

11/08/2012

Company Report

Pages: 11

Q3 results slightly below our estimates, but 2013 looks brighter than ever

Provider: BRINSON PATRICK SECURITIES CORPORATION

Analyst: HIGGINS M

Price: 25.00

Research Provided by a Third Party

Company: Akorn, Inc.

Industry: Medical - Generic Drugs

Record: 6

08/08/2012

Company Report

Pages: 9

Solid fundamentals drive Q2’s results, boosting 2012 guidance

Provider: BRINSON PATRICK SECURITIES CORPORATION

Analyst: HIGGINS M

Price: 25.00

Research Provided by a Third Party

Company: Akorn, Inc.

Industry: Medical - Generic Drugs

Record: 7

06/07/2012

Daily Note

Pages: 5

Termination of Coverage

Provider: AURIGA USA

Price: 10.00

Research Provided by a Third Party

Company: Akorn, Inc.

Industry: Medical - Generic Drugs

Record: 8

05/22/2012

Industry Report

Pages: 14

June Specialty Pharma Catalyst Calendar

Provider: AURIGA USA

Analyst: CHEN L

Price: 50.00

Research Provided by a Third Party

Company: Akorn, Inc.

Industry: Medical - Generic Drugs

Record: 9

05/22/2012

Company Report

Pages: 32

Initiating With Buy and $16 Price Target

Provider: AURIGA USA

Analyst: CHEN L

Price: 75.00

Research Provided by a Third Party

Company: Akorn, Inc.

Industry: Medical - Generic Drugs

Record: 10

05/09/2012

Company Report

Pages: 10

Beats the Street; 2012 Guidance Unchanged.

Provider: BRINSON PATRICK SECURITIES CORPORATION

Analyst: HIGGINS M

Price: 25.00

Research Provided by a Third Party

Company: Akorn, Inc.

Industry: Medical - Generic Drugs

Record: 11

05/04/2012

Company Report

Pages: 13

Buy , ahead of the quarter.

Provider: BRINSON PATRICK SECURITIES CORPORATION

Analyst: HIGGINS M

Price: 50.00

Research Provided by a Third Party

Company: Akorn, Inc.

Industry: Medical - Generic Drugs

Record: 12

03/22/2012

Company Report

Pages: 29

Initiation: Akorn Capitalizing on Drug Shortages, Pipeline Extends the Rally

Provider: BRINSON PATRICK SECURITIES CORPORATION

Analyst: HIGGINS M

Price: 75.00

Research Provided by a Third Party

Company: Akorn, Inc.

Industry: Medical - Generic Drugs

Record: 13

03/22/2012

Daily Note

Pages: 29

Initiation: Akorn Capitalizing on Drug Shortages, Pipeline Extends the Rally

Provider: BRINSON PATRICK SECURITIES CORPORATION

Analyst: HIGGINS M

Price: 75.00

Research Provided by a Third Party

Company: Akorn, Inc.

Industry: Medical - Generic Drugs

Record: 14

10/16/2011

Company Report

Pages: 3

Termination of Coverage

Provider: RODMAN & RENSHAW, CO.

Price: 10.00

Research Provided by a Third Party

Company: Akorn, Inc.

Industry: Medical - Generic Drugs

Record: 15

10/16/2011

Daily Note

Pages: 3

Termination of Coverage

Provider: RODMAN & RENSHAW, CO.

Price: 10.00

Research Provided by a Third Party

Company: Akorn, Inc.

Industry: Medical - Generic Drugs

Record: 16

09/09/2011

Daily Note

Pages: 3

CONFERENCE PREVIEW

Provider: RODMAN & RENSHAW, CO.

Analyst: HIGGINS M

Price: 10.00

Research Provided by a Third Party

Company: Akorn, Inc.

Industry: Medical - Generic Drugs

Record: 17

09/09/2011

Daily Note

Pages: 57

CONFERENCE PREVIEW

Provider: RODMAN & RENSHAW, CO.

Analyst: HIGGINS M

Price: 100.00

Research Provided by a Third Party

Company: Akorn, Inc.

Industry: Medical - Generic Drugs

Record: 18

08/03/2011

Daily Note

Pages: 9

MORNING SUMMARY

Provider: RODMAN & RENSHAW, CO.

Price: 25.00

Research Provided by a Third Party

Company: Akorn, Inc.

Industry: Medical - Generic Drugs

Record: 19

08/03/2011

Daily Note

Pages: 3

Akorn continues to execute..... putting a strong Q2 in the books and raising 2011 guidance

Provider: RODMAN & RENSHAW, CO.

Analyst: HIGGINS M

Price: 10.00

Research Provided by a Third Party

Company: Akorn, Inc.

Industry: Medical - Generic Drugs

Record: 20

08/03/2011

Company Report

Pages: 8

Akorn continues to execute...... putting a strong Q2 in the books and raising 2011 guidance

Provider: RODMAN & RENSHAW, CO.

Analyst: HIGGINS M

Price: 25.00

Research Provided by a Third Party